For research use only. Not for therapeutic Use.
Zilurgisertib（Cat No.:I045086）is an experimental small-molecule inhibitor targeting activin receptor-like kinase 2 (ALK2), a key receptor in the bone morphogenetic protein (BMP) signaling pathway. It is being investigated for the treatment of fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by abnormal bone formation in soft tissues. By selectively inhibiting ALK2, Zilurgisertib aims to reduce heterotopic ossification and disease progression. Its oral bioavailability and specificity make it a promising therapeutic candidate for FOP and other BMP-driven conditions. Supplied for scientific research focused on rare bone disorders.
| CAS Number | 2173389-57-4 |
| Synonyms | 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[(1R,5S)-3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide |
| Molecular Formula | C30H38N4O3 |
| Purity | ≥95% |
| IUPAC Name | 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[(1R,5S)-3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide |
| InChI | InChI=1S/C30H38N4O3/c31-26-25(27(35)33-28-7-10-29(36,11-8-28)12-9-28)15-21(17-32-26)20-1-3-22(4-2-20)30-16-23(30)18-34(19-30)24-5-13-37-14-6-24/h1-4,15,17,23-24,36H,5-14,16,18-19H2,(H2,31,32)(H,33,35)/t23-,28?,29?,30+/m1/s1 |
| InChIKey | KPRPFTOLWQQUAV-OCVAFRRMSA-N |
| SMILES | C1COCCC1N2C[C@H]3C[C@]3(C2)C4=CC=C(C=C4)C5=CC(=C(N=C5)N)C(=O)NC67CCC(CC6)(CC7)O |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
